Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?
Vaccines for infectious diseases have improved the life of the human species in a tremendous manner. The principle of vaccination is to establish de novo adaptive immune response consisting of antibody and T cell responses against pathogens which should defend the vaccinated person against future ch...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01368/full |
| _version_ | 1818958553525780480 |
|---|---|
| author | Inna Tulaeva Inna Tulaeva Bernhard Kratzer Raffaela Campana Mirela Curin Marianne van Hage Antonina Karsonova Ksenja Riabova Alexander Karaulov Musa Khaitov Winfried F. Pickl Rudolf Valenta Rudolf Valenta Rudolf Valenta Rudolf Valenta |
| author_facet | Inna Tulaeva Inna Tulaeva Bernhard Kratzer Raffaela Campana Mirela Curin Marianne van Hage Antonina Karsonova Ksenja Riabova Alexander Karaulov Musa Khaitov Winfried F. Pickl Rudolf Valenta Rudolf Valenta Rudolf Valenta Rudolf Valenta |
| author_sort | Inna Tulaeva |
| collection | DOAJ |
| description | Vaccines for infectious diseases have improved the life of the human species in a tremendous manner. The principle of vaccination is to establish de novo adaptive immune response consisting of antibody and T cell responses against pathogens which should defend the vaccinated person against future challenge with the culprit pathogen. The situation is completely different for immunoglobulin E (IgE)-associated allergy, an immunologically-mediated hypersensitivity which is already characterized by increased IgE antibody levels and T cell responses against per se innocuous antigens (i.e., allergens). Thus, allergic patients suffer from a deviated hyper-immunity against allergens leading to inflammation upon allergen contact. Paradoxically, vaccination with allergens, termed allergen-specific immunotherapy (AIT), induces a counter immune response based on the production of high levels of allergen-specific IgG antibodies and alterations of the adaptive cellular response, which reduce allergen-induced symptoms of allergic inflammation. AIT was even shown to prevent the progression of mild to severe forms of allergy. Consequently, AIT can be considered as a form of therapeutic vaccination. In this article we describe a strategy and possible road map for the use of an AIT approach for prophylactic vaccination against allergy which is based on new molecular allergy vaccines. This road map includes the use of AIT for secondary preventive vaccination to stop the progression of clinically silent allergic sensitization toward symptomatic allergy and ultimately the prevention of allergic sensitization by maternal vaccination and/or early primary preventive vaccination of children. Prophylactic allergy vaccination with molecular allergy vaccines may allow halting the allergy epidemics affecting almost 30% of the population as it has been achieved for vaccination against infectious diseases. |
| first_indexed | 2024-12-20T11:27:35Z |
| format | Article |
| id | doaj.art-745199fe68b54a1293b0d3a09aead1ee |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-20T11:27:35Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-745199fe68b54a1293b0d3a09aead1ee2022-12-21T19:42:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-07-011110.3389/fimmu.2020.01368535078Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?Inna Tulaeva0Inna Tulaeva1Bernhard Kratzer2Raffaela Campana3Mirela Curin4Marianne van Hage5Antonina Karsonova6Ksenja Riabova7Alexander Karaulov8Musa Khaitov9Winfried F. Pickl10Rudolf Valenta11Rudolf Valenta12Rudolf Valenta13Rudolf Valenta14Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaLaboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, RussiaCenter for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, AustriaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaDivision of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, SwedenLaboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, RussiaLaboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, RussiaLaboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, RussiaNRC Institute of Immunology FMBA of Russia, Moscow, RussiaCenter for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, AustriaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaLaboratory of Immunopathology, Department of Clinical Immunology and Allergology, Sechenov First Moscow State Medical University, Moscow, RussiaNRC Institute of Immunology FMBA of Russia, Moscow, RussiaKarl Landsteiner University of Health Sciences, Krems an der Donau, AustriaVaccines for infectious diseases have improved the life of the human species in a tremendous manner. The principle of vaccination is to establish de novo adaptive immune response consisting of antibody and T cell responses against pathogens which should defend the vaccinated person against future challenge with the culprit pathogen. The situation is completely different for immunoglobulin E (IgE)-associated allergy, an immunologically-mediated hypersensitivity which is already characterized by increased IgE antibody levels and T cell responses against per se innocuous antigens (i.e., allergens). Thus, allergic patients suffer from a deviated hyper-immunity against allergens leading to inflammation upon allergen contact. Paradoxically, vaccination with allergens, termed allergen-specific immunotherapy (AIT), induces a counter immune response based on the production of high levels of allergen-specific IgG antibodies and alterations of the adaptive cellular response, which reduce allergen-induced symptoms of allergic inflammation. AIT was even shown to prevent the progression of mild to severe forms of allergy. Consequently, AIT can be considered as a form of therapeutic vaccination. In this article we describe a strategy and possible road map for the use of an AIT approach for prophylactic vaccination against allergy which is based on new molecular allergy vaccines. This road map includes the use of AIT for secondary preventive vaccination to stop the progression of clinically silent allergic sensitization toward symptomatic allergy and ultimately the prevention of allergic sensitization by maternal vaccination and/or early primary preventive vaccination of children. Prophylactic allergy vaccination with molecular allergy vaccines may allow halting the allergy epidemics affecting almost 30% of the population as it has been achieved for vaccination against infectious diseases.https://www.frontiersin.org/article/10.3389/fimmu.2020.01368/fullvaccinevaccinationallergyallergenallergen-specific immunotherapytherapeutic vaccine |
| spellingShingle | Inna Tulaeva Inna Tulaeva Bernhard Kratzer Raffaela Campana Mirela Curin Marianne van Hage Antonina Karsonova Ksenja Riabova Alexander Karaulov Musa Khaitov Winfried F. Pickl Rudolf Valenta Rudolf Valenta Rudolf Valenta Rudolf Valenta Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? Frontiers in Immunology vaccine vaccination allergy allergen allergen-specific immunotherapy therapeutic vaccine |
| title | Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? |
| title_full | Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? |
| title_fullStr | Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? |
| title_full_unstemmed | Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? |
| title_short | Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? |
| title_sort | preventive allergen specific vaccination against allergy mission possible |
| topic | vaccine vaccination allergy allergen allergen-specific immunotherapy therapeutic vaccine |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2020.01368/full |
| work_keys_str_mv | AT innatulaeva preventiveallergenspecificvaccinationagainstallergymissionpossible AT innatulaeva preventiveallergenspecificvaccinationagainstallergymissionpossible AT bernhardkratzer preventiveallergenspecificvaccinationagainstallergymissionpossible AT raffaelacampana preventiveallergenspecificvaccinationagainstallergymissionpossible AT mirelacurin preventiveallergenspecificvaccinationagainstallergymissionpossible AT mariannevanhage preventiveallergenspecificvaccinationagainstallergymissionpossible AT antoninakarsonova preventiveallergenspecificvaccinationagainstallergymissionpossible AT ksenjariabova preventiveallergenspecificvaccinationagainstallergymissionpossible AT alexanderkaraulov preventiveallergenspecificvaccinationagainstallergymissionpossible AT musakhaitov preventiveallergenspecificvaccinationagainstallergymissionpossible AT winfriedfpickl preventiveallergenspecificvaccinationagainstallergymissionpossible AT rudolfvalenta preventiveallergenspecificvaccinationagainstallergymissionpossible AT rudolfvalenta preventiveallergenspecificvaccinationagainstallergymissionpossible AT rudolfvalenta preventiveallergenspecificvaccinationagainstallergymissionpossible AT rudolfvalenta preventiveallergenspecificvaccinationagainstallergymissionpossible |